drugset / Trial / NCT04265053
Human Cerebral Blood Flow Regulation
Phase 0
Completed
42 enrolled
University of Wisconsin, Madison
National Heart, Lung, and Blood Institute (NHLBI) · collab
Non-randomizedParallel-groupOpen-labelBasic science
Summary
To determine cerebrovascular control mechanisms in humans and provide mechanistic knowledge to offer new sex-specific therapeutic options for cerebrovascular diseases. The current objective is to determine how sex and sex hormones influence CBF control in healthy young adults without confounds of age or disease. The central hypothesis is men exhibit reduced cerebral vasodilator function due in part to differences in COX signaling compared to women. Comprehensive CBF data from multi-modal MRI indicate the magnitude of sex differences-as well as the vasodilator mechanisms-are regionally distinct. Research confounding variables like aging and disease will be mitigated by comparing younger adults (18-40 years old).
Timeline
- Start
- 2021-04-12
- Primary completion
- 2025-03-31
- Completion
- 2025-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Indomethacin | Small molecule | 25 mg | — |
| Subject | Indomethacin | Small molecule | 50 mg | — |